Acrivastine
Histamine-1 Receptor Antagonist — RESPIRATORY SYSTEM
Also known as: BW-270C, BW-825C, semprex
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Acrivastine is an ofm drug in the Histamine-1 Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1994. Its mechanism of action is classified as Histamine H1 Receptor Antagonists. DrugCentral lists 3 molecular targets, including HRH1, HRH1 and ABCB1. Recorded indications include Allergic conjunctivitis, Allergic rhinitis, Common cold and Nasal congestion.
- Approval status: ofm (first approved 1994 by the FDA).
- Drug class: Histamine-1 Receptor Antagonist.
- Mechanism of action: Histamine H1 Receptor Antagonists.
- Molecular targets: HRH1, HRH1 and ABCB1 (3 listed in DrugCentral).
- Indications: Allergic conjunctivitis, Allergic rhinitis, Common cold, Nasal congestion and Nasal discharge and others.
- ATC code: R06AX18 (Other antihistamines for systemic use).
- Molecular formula: C22H24N2O2; molecular weight 348.45 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (8)
- Allergic conjunctivitis
- Allergic rhinitis
- Common cold
- Nasal congestion
- Nasal discharge
- Seasonal allergic rhinitis
- Sneezing
- Vasomotor rhinitis
Contraindications (8)
- Angle-closure glaucoma
- Benign prostatic hyperplasia
- Coronary arteriosclerosis
- Diabetes mellitus
- Hypertensive disorder
- Hypertensive urgency
- Hyperthyroidism
- Retention of urine
Mechanism & targets
| Mechanism of action (MoA) | Histamine H1 Receptor Antagonists |
|---|---|
| Established pharmacologic class | Histamine-1 Receptor Antagonist |
Molecular targets (3)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Histamine H1 receptor | HRH1 | antagonist | IC50 7.16 |
| Histamine H1 receptor | HRH1 | unknown | IC50 5.21 |
| Multidrug resistance protein 1 | ABCB1 | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1994-03-25 | FDA | — | AUXILIUM PHARMS INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
R06AX18 | RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Other antihistamines for systemic use |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Total lung capacity increased | 382.9 |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | 363.3 |
| Hypomania | 338.4 |
| Jaundice cholestatic | 315.3 |
| Nasal polyps | 298.0 |
| Sarcoidosis | 297.7 |
| Rhinitis allergic | 277.5 |
| Schizophrenia | 273.8 |
| Cardiac murmur | 237.9 |
| Bronchiectasis | 218.4 |
| Psychotic disorder | 208.1 |
| Lung neoplasm malignant | 198.7 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Acrivastine is on its molecule page.
| Molecular formula | C22H24N2O2 |
|---|---|
| Molecular weight | 348.45 g/mol |
| CAS number | 87848-99-5 |
| InChIKey | PWACSDKDOHSSQD-IUTFFREVSA-N |
| PubChem CID | 5284514 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Acrivastine used for?
DrugCentral lists the following indications for Acrivastine: Allergic conjunctivitis, Allergic rhinitis, Common cold, Nasal congestion, Nasal discharge, Seasonal allergic rhinitis, Sneezing and Vasomotor rhinitis.
How does Acrivastine work?
Acrivastine is classified as Histamine H1 Receptor Antagonists; its molecular targets in DrugCentral include HRH1 (antagonist), HRH1 and ABCB1.
When was Acrivastine first approved?
Acrivastine was first approved by the FDA in 1994.
What drug class does Acrivastine belong to?
Acrivastine is in the Histamine-1 Receptor Antagonist class.
What is the chemical formula of Acrivastine?
Acrivastine has the molecular formula C22H24N2O2 and a molecular weight of 348.45 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 82 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1224 — compound record and bioactivity
- PubChem CID 5284514 — chemical identifiers
- DrugBank DB09488 — drug record
- FDA UNII A20F9XAI7W — substance identity
- DailyMed: FDA labels for Acrivastine — current prescribing information (label search)
- UniProt P35367 (HRH1) — target protein
- UniProt P08183 (ABCB1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.